CD8A and neoplasm: Furthermore, inhibiting KRASG12D mutant protein with MRTX1133 has been shown to reverse early PDAC lesions, reduce tumor burden, and promote CD8+ T cell-mediated cytotoxicity by inducing FAS expression, which increases CD8+ T cells in tumors and reprograms CAFs (112).